The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 36.80
Bid: 36.60
Ask: 37.30
Change: 0.00 (0.00%)
Spread: 0.70 (1.913%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 36.80
FUM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Licenses CSD500 to RFSU AB in the Nordic Region

19 Dec 2013 07:00

RNS Number : 9135V
Futura Medical PLC
19 December 2013
 

For immediate release

19 December 2013

 

 

Futura Medical PLC

("Futura" or the "Company")

 

Licenses CSD500 to RFSU AB in the Nordic Region

 

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, announces that it has signed an exclusive licensing agreement with Sweden's RFSU AB for the marketing and distribution of CSD500, Futura's novel condom, in Sweden, Norway, Finland and Denmark.

 

This agreement is in line with Futura's strategy of licensing CSD500 to condom distributors that hold leading positions in their regions. RFSU AB is the market leader in the four Nordic countries included in this agreement.

 

Regulatory authorisation in all of the countries included in this agreement is provided by CSD500's CE mark, which was awarded earlier this year.

 

Under the terms of the agreement, RFSU AB will hold the rights to manufacture, market and distribute CSD500 in Sweden, Norway, Finland and Denmark.

 

The financial details of the agreement are not being disclosed although Futura will receive an upfront payment and royalties on all product sales along with certain minimum performance guarantees.

 

Katarina Knutz, Managing Director of RFSU AB, commented: "Our objective is to promote innovation in condom design to provide choice to our customers. CSD500 is a highly attractive addition to our product portfolio as the uniqueness of its design brings the potential to encourage the wider use of condoms."

 

James Barder, Futura's Chief Executive, commented: "We are delighted to sign this exclusive agreement with RFSU AB for the marketing of CSD500 in Sweden, Norway, Finland and Denmark. RFSU AB has leading market positions in these four countries, all of which use the CE mark for regulatory authorisation. We look forward to RFSU AB's launch of CSD500 in the Nordic Region during 2014."

 

 

For further information:

 

Futura Medical plc

+ 44 (0) 1483 685 670

James Barder, Chief Executive

Mail to: James.Barder@futuramedical.com

www.futuramedical.com

Cenkos Securities plc

+ 44 (0) 20 7397 8927

Bobbie Hilliam

 

Buchanan

+ 44 (0) 20 7466 5000

Mark Court / Fiona Henson / Sophie Cowles

 

 

Notes to editors:

 

About Futura Medical plc

 

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

 

www.futuramedical.com 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCQVLFFXLFZFBQ
Date   Source Headline
29th Apr 20247:00 amRNSDirectors’ / PDMR Dealing and Grant of Options
10th Apr 20247:00 amRNSResults for the Year ended 31 December 2023
25th Mar 20247:00 amRNSNotice of Results and Investor Presentation
14th Feb 20247:00 amRNSEroxon to be available on prescription
6th Feb 20247:01 amRNSTrading Update
6th Feb 20247:00 amRNSAppointment of Joint Corporate Broker
17th Jan 20247:00 amRNSDirector/PDMR Dealing
17th Jan 20247:00 amRNSRemuneration of Non-Exec Directors & Voting Rights
15th Jan 20247:00 amRNSFutura Medical extends collaboration with Cooper
9th Jan 20247:00 amRNSAppointment of Roy Davis as Non-Executive Director
30th Nov 20233:10 pmRNSTotal Voting Rights
30th Nov 20233:10 pmRNSBlock Listing Six Monthly Return
7th Nov 20237:00 amRNSFutura expands partnership with M8 Pharmaceuticals
2nd Nov 20233:34 pmRNSEroxon Awarded “New Product of the Year” by Boots
31st Oct 20237:00 amRNSBlock Listing Application and Total Voting Rights
25th Oct 20237:00 amRNSEroxon® Granted Marketing Authorisation in Mexico
19th Oct 20237:00 amRNSEroxon Launches in the United Arab Emirates
10th Oct 20237:00 amRNSDirectors’/PDMR Dealing and Grant of Options
2nd Oct 20237:00 amRNSEuropean Patent Granted for MED3000 until 2040
18th Sep 20237:00 amRNSFutura Medical - Interim Results 2023
18th Aug 20237:00 amRNSFutura Medical - Notice of Interim Results
31st Jul 20237:00 amRNSFutura Medical - Total Voting Rights
18th Jul 202311:04 amRNSBoard Change
17th Jul 20237:00 amRNSFutura/Haleon Enter US Commercialisation Agreement
30th Jun 20237:00 amRNSFutura Medical - Total Voting Rights
23rd Jun 20234:30 pmRNSRecording of Investor Seminar
22nd Jun 20233:19 pmRNSFutura Medical Annual General Meeting Results
22nd Jun 20237:00 amRNSFutura Medical AGM Statement
19th Jun 202310:25 amRNSCorrection - TR-1: Notification of major holdings
16th Jun 20234:05 pmRNSTR-1: Notification of major holdings
12th Jun 20238:23 amRNSExercise of Warrants
12th Jun 20237:00 amRNSMED3000 Granted US FDA Approval for OTC Sale
8th Jun 20237:00 amRNSFutura Medical Announces Investor Seminar
31st May 20237:00 amRNSBlock Listing Six Monthly Return
26th May 20237:00 amRNSNotice of AGM and availability of Annual Report
24th Apr 20237:00 amRNSTR-1: Notification of major holdings
18th Apr 20237:00 amRNSMED3000, Eroxon® UK Launch
6th Apr 202311:03 amRNSDirectors' / PDMR Dealing and Grant of Options
5th Apr 20237:00 amRNSFull Year Results ended 31 December 2022
29th Mar 20237:00 amRNSUpdate on MED3000 regulatory approval in the US
27th Mar 20235:24 pmRNSNotice of Preliminary Results 2022
14th Mar 20238:33 amRNSMED3000 commercial and US regulatory update
15th Feb 20237:00 amRNSMED3000 FM71 Presentation at ESSM Congress 2023
1st Feb 20231:26 pmRNSBlock Listing Applications to AIM
26th Jan 20237:00 amRNSPre-launch of MED3000 ahead of H1 2023 launch
12th Jan 202311:09 amRNSFutura Remuneration, Options & Total Voting Rights
15th Dec 20223:01 pmRNSTR-1: Notification of major holdings
13th Dec 20221:10 pmEQSFutura Medical 'on track' for launch in H1 2023
13th Dec 20227:00 amRNSFutura Medical announce milestone year for MED3000
30th Nov 20227:00 amRNSFutura Block Listing Six Monthly Return

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.